SEC Comment Letter for INVIVO THERAPEUTICS HOLDINGS CORP. (CIK 0001292519) — Feb 28, 2020
INVIVO THERAPEUTICS HOLDINGS CORP. (CIK 0001292519)
Date: Feb. 28, 2020 · CIK: 0001292519 · Accession: 0000000000-20-001848
AI Filing Summary & Sentiment
File numbers found in text: 333-236572
Letter
February 28, 2020 Richard Toselli, M.D. President and Chief Executive Officer InVivo Therapeutics Holdings Corp. One Kendall Square, Suite B14402 Cambridge, MA 02139 Re:InVivo Therapeutics Holdings Corp. Registration Statement on Form S-1 Filed February 21, 2020 File No. 333-236572 Dear Dr. Toselli: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Jeffrey Gabor at 202-551-2544 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc: Rosemary G. Reilly, Esq.
Show Raw Text
February 28, 2020
Richard Toselli, M.D.
President and Chief Executive Officer
InVivo Therapeutics Holdings Corp.
One Kendall Square, Suite B14402
Cambridge, MA 02139
Re:InVivo Therapeutics Holdings Corp.
Registration Statement on Form S-1
Filed February 21, 2020
File No. 333-236572
Dear Dr. Toselli:
This is to advise you that we have not reviewed and will not review your registration
statement.
Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you
that the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.
Please contact Jeffrey Gabor at 202-551-2544 with any questions.
Sincerely,
Division of Corporation Finance
Office of Life Sciences
cc: Rosemary G. Reilly, Esq.